Agilent Technologies, Inc. (A) Stock: Price, Forecast & Analyst Target
Agilent Technologies, Inc. (A) — MoonshotScore 83/100 (Exceptional band), calculated Nov 18, 2026. Price $175.34 (-1.12%), as of the Nov 19, 2026 trading session; market cap $49.4B. Expected results Nov 23, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Agilent Technologies, Inc. · A · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Agilent Technologies equips laboratories with analytical instruments, diagnostics and genomics tools, then supports their operation through CrossLab consumables and services. Its economics therefore depend on both laboratory investment and continuing use of installed workflows. Recent growth and profit expansion make demand durability—and the timing of management’s anticipated reshoring benefit—the key issue to follow.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Agilent Technologies (A)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Nov 23, 2026
- Altman Z 5.75 · Piotroski F 6
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 82 | Exceptional | |
| 81 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $175.34 | |
| Change on the day | -1.12% | |
| 52-week range | $108.35–$182.99 | |
| Market capitalisation | $49.4B | — |
| Price / earnings (trailing) | 33.83 | |
| Shares traded on the day | 2.13M | |
| Beta (volatility vs the S&P 500) | 1.24 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Agilent Technologies (A): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Agilent Technologies (A), and what does it report?
Short answer · as of
Agilent is not simply a diagnostics company. It sells chromatography, mass spectrometry, spectroscopy and cell-analysis systems to life-science and applied-markets laboratories; diagnostics and genomics products span tissue staining, genetic analysis, sequencing preparation and custom oligonucleotides.
Research dated 2026-09-12.
CrossLab adds columns, sample-preparation supplies, software, compliance support, asset management and laboratory services.
Reported revenue consequently blends instrument purchases with consumables and service activity tied to laboratory operations. CrossLab is the largest disclosed segment, making recurring laboratory support economically important alongside demand for new systems.
What do the latest results show for Agilent Technologies (A)?
Research dated 2026-09-12.
Revenue, gross profit and operating profit have risen sequentially across the latest reported periods, while net income and diluted earnings also recovered from the recent low. The latest result exceeded revenue and earnings expectations, extending the improvement seen in the preceding report after an earlier shortfall.
The statements show the recovery but do not isolate its operating cause. Management raised its fiscal revenue outlook and said pharma reshoring should begin producing more meaningful orders around year-end, with revenue building later; that frames reshoring as an emerging contributor rather than an explanation for all of the current improvement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | Not available | Not available | Not available | Not available |
| Apr 30, 2026 | Not available | Not available | Not available | Not available |
| Jan 31, 2026 | Not available | Not available | Not available | Not available |
| Oct 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jul 2025 | $1.74B | $336M | $1.18 (diluted) |
| Q4 FY2025 | $1.86B | $434M | $1.53 (diluted) |
| Q1 FY2026 | $1.80B | $305M | $1.07 (diluted) |
| Q2 FY2026 | $1.83B | $339M | $1.20 (diluted) |
What are the financial strengths and risks for Agilent Technologies (A)?
Short answer
Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Agilent remains profitable and consistently generates positive operating cash flow, with the latest period showing a sharp cash-generation rebound. Cash and short-term investments have also increased over the reported span, while liquidity ratios indicate ample coverage of near-term obligations.
Debt nevertheless exceeds cash and investments, leaving Agilent in a net-debt position. That matters because the shares trade at a substantial earnings and sales valuation: weakening laboratory demand could pressure instrument revenue while selling and research costs continue, making sustained profit conversion more important than revenue growth alone. Distress and operating-quality screens are presently constructive, but they do not remove that valuation sensitivity.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 33.83 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Agilent Technologies (A)?
Short answer · as of
The next earnings report is expected on Nov 23, 2026.
Research dated 2026-09-12.
Watch whether revenue and operating profit continue their recent sequential climb, whether operating cash flow holds near its stronger recent level, and whether another earnings report clears market expectations. A reversal in any of those measures would weaken the evidence that the recovery is broadening.
Management has supplied a more company-specific checkpoint: pharma reshoring orders are expected to become more meaningful around year-end, followed by revenue contribution later. The useful confirmation would be visible order momentum that ultimately reaches reported sales, while the upcoming report provides the nearer test of the raised outlook.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Agilent Technologies compare with its peers?
Short answer
Agilent Technologies's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Agilent combines complex analytical hardware with the supplies, software and services needed to keep laboratory workflows running. Compared with businesses dependent mainly on new equipment placements, CrossLab gives Agilent exposure to ongoing instrument use through columns, sample preparation, compliance, training and asset management.
Its diagnostics and genomics portfolio also reaches beyond analytical chemistry into tissue staining, genetic analysis and sequencing preparation. The relevant comparison is therefore not merely instrument breadth, but the mix of capital equipment, laboratory usage revenue and clinically oriented tools inside the same company.
| Company | Price | Market value | Score |
|---|---|---|---|
| $689.65 Nov 19, 2026 | $54.3B | 96 5-pillar Nov 18, 2026 | |
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $1705.66 Nov 19, 2026 | $33.9B | 93 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| Agilent Technologies (A) — this page | $175.34 | $49.4B | 83 |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $258.99 Nov 19, 2026 | $28.5B | 74 5-pillar Nov 18, 2026 | |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $150.00 – $195.00
- Consensus target
- $174.29
- Median target
- $177.50
Consensus record · Captured .
Measured against a quoted price of $175.34 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 5
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 2
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held A in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.92% | $301.78M | New position |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.27% | $61.28M | Added +1453.7% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Agilent Technologies (A)?
Agilent Technologies Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Agilent CrossLab matter to Agilent’s business model?
CrossLab sells laboratory consumables and operational services rather than relying on new instrument purchases alone. Its position as Agilent’s largest disclosed segment makes ongoing laboratory activity a major part of the company’s revenue mix.
What do Agilent’s chromatography and mass spectrometry systems measure economically?
They represent laboratory capital demand, but they also create workflows that use columns, sample-preparation products, software and support. Agilent participates in both the equipment decision and the continuing operation of the laboratory.
Is pharma reshoring already the main driver of Agilent’s growth?
Management described the more meaningful order benefit as approaching around year-end and the revenue contribution as building later. The current recovery should therefore be judged on reported performance without treating the anticipated reshoring benefit as fully realized.
What would confirm that Agilent’s recent earnings recovery is durable?
Further revenue and operating-profit progression, continued positive cash generation and delivery against the raised outlook would strengthen the case. Order momentum from pharma reshoring would add a distinct source of confirmation beyond another expectations beat.
What is the A stock price today?
The last price recorded for Agilent Technologies, Inc. (A), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the A price target?
The analyst consensus price target for Agilent Technologies, Inc. (A), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold A
Funds in our ETF coverage that list A among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Madison Covered Call ETF (CVRD) | 3.18% |